Jim Cramer still says to hold Apple, not trade it, but shares why he feels indifferent to its upcoming quarter. » Read More
By: Elizabeth Gurdus
Jim Cramer takes to the charts with Marc Chaikin to see if shares of Centene, Cardinal Health and Amgen have more room to run. » Read More
By: Steve Kraus, Bessemer Venture Partners
This time will be different, says Bessemer Venture Partners' health investor Steve Kraus. » Read More
By: Dan Mangan
Azar is replacing Dr. Tom Price, who resigned amid controversy last fall over his use of private pricey charter flights for work. » Read More
The Trump administration has taken steps that will hinder federal efforts to fight opioids, say Chris Lu and Allison Hunn.
Three big health insurers and the nation's largest for-profit hospital operator plan to give fourth quarter results.
Health-care firms are making a hard push to engage patients on their mobile phones.
Experts said insurers risk big fines and lawsuits if they accepted Idaho's offer to issue health plans not compliant with Obamacare.
One possible reason why, according to the Centers for Disease Control and Prevention: a phenomenon called imprinting.
Flu activity has been elevated for nine consecutive weeks this season, said the Centers for Disease Control and Prevention.
Biotech firms are exploring new techniques to develop a universal flu vaccine. The lack of federal funding is making this difficult.
AbbVie Inc reported fourth-quarter profit that beat Wall Street estimates on strong sales for its blockbuster drug Humira.
The Satanic Temple says its members and others should be able to claim exemptions from the Missouri law on religious grounds.
A recent study found that heart attacks are six times more likely seven days after a flu diagnosis, USA Today reports.
The Red Cross helped a senior official, accused of misconduct, land a job at Save the Children, ProPublica reported.
Biogen reported fourth-quarter revenue of $3.31 billion, above the $3.1 billion expected from analysts polled by Thomson Reuters.
An FDA advisory committee said evidence doesn't support the tobacco company's claim that iQOS cuts the risk of tobacco-related diseases.
Philadelphia is now angling to become the first city with a legally sanctioned safe injection site, Vox reports.
A failed attempt to market iQOS as safer than cigarettes could still be a win for Philip Morris, says a former FDA official.
J&J's decision leaves the drugmaker with one less big bidder, which may affect its negotiating power.
Get the best of CNBC in your inbox